Chris Degnan

CIK: 0001741968

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

URGN

UroGen Pharma Ltd.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

URGN
UroGen Pharma Ltd.
Oct 8, 2026
Exercise(M)
Direct
4.5K shares-
URGN
UroGen Pharma Ltd.
Oct 8, 2026
Sale(S)
Direct
2.2K shares at avg. $36.69$81K
URGN
UroGen Pharma Ltd.
Jan 31, 2026
Award(A)
Restricted Stock Units
Direct
32.6K shares-
URGN
UroGen Pharma Ltd.
Oct 8, 2025
Sale(S)
Direct
2.2K shares at avg. $16.85$37K
URGN
UroGen Pharma Ltd.
Oct 8, 2025
Exercise(M)
Direct
4.5K shares-
URGN
UroGen Pharma Ltd.
Oct 8, 2024
Award(A)
Restricted Stock Units
Direct
13.5K shares-
URGN
UroGen Pharma Ltd.
Oct 8, 2024
Award(A)
Employee Stock Option (right to buy)
Direct
74.1K shares-

		Type	Shares	Price		Ownership
Oct 8, 2026	URGN UroGen Pharma Ltd.	Exercise(M)	4,483	-	$0	Direct
Oct 8, 2026	URGN UroGen Pharma Ltd.	Sale(S)	2,202	$36.69	$80,791	Direct
Jan 31, 2026	URGN UroGen Pharma Ltd.	Award(A) Restricted Stock Units	32,609	-	-	Direct
Oct 8, 2025	URGN UroGen Pharma Ltd.	Sale(S)	2,203	$16.85	$37,121	Direct
Oct 8, 2025	URGN UroGen Pharma Ltd.	Exercise(M)	4,483	-	-	Direct
Oct 8, 2024	URGN UroGen Pharma Ltd.	Award(A) Restricted Stock Units	13,450	-	-	Direct
Oct 8, 2024	URGN UroGen Pharma Ltd.	Award(A) Employee Stock Option (right to buy)	74,142	-	-	Direct

1-7 of 7 transactions

About Degnan Chris

Degnan Chris (SEC CIK 0001741968) files insider reports with the SEC as Chief Financial Officer of UroGen Pharma Ltd. (URGN).

Signal8 holds 5 ownership filings by Degnan Chris (1 Form 3, 4 Form 4), filed between Oct 9, 2024 and Oct 9, 2026. Those filings report 7 transactions, from Oct 8, 2024 to Oct 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Degnan Chris's filings is in PRINCETON, NJ.

Recent filings by Degnan Chris

Oct 8, 2026: Option exercise of URGN shares (Form 4, code M).
Oct 8, 2026: Open-market sale of URGN shares (Form 4, code S).
Jan 31, 2026: Grant or award of URGN derivative securities (Form 4, code A).
Oct 8, 2025: Open-market sale of URGN shares (Form 4, code S).
Oct 8, 2025: Option exercise of URGN shares (Form 4, code M).

Other insiders filing for UroGen Pharma Ltd. (URGN)

Schoenberg Mark, Chief Medical Officer
Smith Jason Drew, General Counsel
Robinson James A. Jr., Director
Wildman Daniel George, Director
Holden Stuart, Director
BUTITTA CYNTHIA M, Director

How to read Form 4 transaction codes